AI Article Synopsis
- PRP (Pityriasis Rubra Pilaris) is a rare skin condition with unclear causes and no established treatment guidelines, making it challenging for healthcare providers.
- A study involving 65 patients, the largest European series on PRP, revealed that it primarily affects men, with an average age of 51, while older patients (average age 61) often present with more severe erythrodermic forms.
- The results showed that most younger patients and non-erythrodermic adults managed their condition with topical corticosteroids, whereas a significant number of erythrodermic patients needed biologic therapy, taking about 6.5 months for a complete response.
Article Abstract
Introduction: PRP is a rare entity of unknown etiopathogenesis. Lack of management guidelines makes it a challenge for clinicians.
Objective: To add our experience to increase evidence about PRP.
Methods: We performed a retrospective, descriptive and multicentric study of 65 patients with PRP, being the largest European case series of patients with PRP.
Results: PRP was more frequent in male patients with an average age of 51 years, but erythrodermic forms presented in older patients (average age 61 years). Six (75%) paediatric patients and ten (60%) non-erythrodermic adults controlled their disease with topical corticosteroids. On the contrary, 26 (68%) erythrodermic patients required biologic therapy as last and effective therapy line requiring an average of 6.5 months to achieve complete response.
Conclusion: Our study showed a statistical difference in terms of outcome and response to treatment between children or patients with limited disease and patients who develop erythroderma.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1016/j.ad.2024.02.019 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!